Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve 1. The audited financial results of the Company for the quarter and year ended March 31, 2026. 2. To recommend Dividend, if any, on the equity shares of the Company for the financial year 2025-26. We also inform you that the 'Trading Window' remains closed for all Designated Persons, from March 16, 2026 to May 28, 2026 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.